Navigation Links
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
Date:4/17/2009

Pharmacyclics to maintain all US Rights

Conference Call to discuss the company's third quarter financial results is scheduled for April 23, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT).

SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of Pharmacyclics' PCI-24781, an orally active, novel, small molecule inhibitor of Pan HDAC enzymes, that is currently in Phase I/II clinical trials in the United States and being developed for the treatment of solid tumors and hematologic malignancies. Pharmacyclics expects that this alliance will enable it to aggressively pursue its goal of developing and commercializing its innovative anti-cancer Pan HDAC inhibitor agents.

"This alliance with Servier allows us to accelerate our productive discovery efforts, to expand our clinical development capabilities and potentially commercialize our unique and differentiated Pan HDAC inhibitor product outside of the United States in rapid fashion," said Robert W. Duggan, Chairman and Chief Executive Officer of Pharmacyclics. "We are honored to be partnering with the Servier Company, they are incredibly professional in all aspects of their business dealings. Their success and advancement of human healthcare is respected around the world."

Under the terms of the agreement, Servier acquired the exclusive right to develop and commercialize the Pan HDAC inhibitor product worldwide except for the United States and will pay a royalty to Pharmacyclics on sales outside of the United States. Pharmacyclics will continue to own all rights within the United States. Pharmacyclics will re
'/>"/>

SOURCE Pharmacyclics, Inc.

http://www.pharmacyclics.com

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved


0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
2. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
3. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
4. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
5. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
6. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
7. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
8. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
9. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
10. Premier Research Announces Milestone Investigational New Drug Application
11. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...A, Switzerland, Nov. 25 From Nove...novative hearing solutions, presented the second e...focusing on the special needs of the older populat...ts in aging and audiology from around the world an...older people with hearing loss for an opportunity ...
(Date:11/25/2009)..., Nov. 25 The FDA granted traditio...ets, a non-nucleoside reverse transcriptase inhibi...lly indicated for use in treatment-experienced adu...V-1 strains resistant to an NNRTI and other antire...s based on 48-week data from two Phase 3 studies k...
(Date:11/25/2009)...Md., Nov. 25 Remedium T...ream-like foam that stops severe bleeding, won fir...y Idea category of the Global Security Challenge 2...ted from more than 100 entries from around the wor... GSC Security Summit conference held at the London...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Next Stage Solutions Announces Three New Financial Services For Emerging Business 12570 1Next Stage Solutions Announces Three New Financial Services For Emerging Business 12570 2Next Stage Solutions Announces Three New Financial Services For Emerging Business 12570 3TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 1TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 2TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 3TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 4More Than 9 in 10 Primary Care Physicians Say U S Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 48513 1More Than 9 in 10 Primary Care Physicians Say U S Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 48513 2More Than 9 in 10 Primary Care Physicians Say U S Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 48513 3More Than 9 in 10 Primary Care Physicians Say U S Health Care System Should Place Greater Emphasis on Nutrition to Manage Chronic Disease 48513 4
...ical Company,Limited (Takeda) announced today that...ch & Development Center, Inc. (U.S.), submitted a ...ug Administration (FDA) for,marketing approval of ...l),("alogliptin/ACTOS") in a single tablet for the...scovered by Takeda,s wholly owned subsidiary, Take...
...er Supports Spiriva,s Safety,Profile, RIDGEFIELD,...m and Pfizer Inc have released a new analysis of 3... UPLIFT, confirming the long term,safety profile o...alation,powder). The new and expanded safety data ... article by Singh et al. published in the Septembe...
Other Medicine Technology:Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes 2Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes 3Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT 2Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT 3Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT 4Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT 5
(Date:11/27/2009)...vehicles may reduce future disease burden, researc...News) -- Encouraging city dwellers to walk and bic...r public health benefits than increased used of lo..., The study compared the projected health effec...narios for London, England, and Delhi, India: bus...
(Date:11/27/2009)...h™ announced today that Spectrum Health (Gra...terprise orthopedic templating solution and its Tr... (PRWEB) November 27, 2009 -- Voyant Hea...rand Rapids, Michigan) has licensed its TraumaCad ...TraumaCad Extend workflow solution, to allow its o...
(Date:11/27/2009)...teractive anatomy education apps from Modality and...ciences learning opportunities for iPhone and iPod...s) November 27, 2009 -- Modality, Inc. and Lippi...Wolters Kluwer Health, today announced the availab...pp Store. Clemente’s Anatomy, Rohen’s ...
(Date:11/26/2009)...Americans living with diabetes will nearly double,...ion in 2034. Over the same period, spending on dia... to $336 billion, even with no increase in the pre...rsity of Chicago report in the December issue of ...tes covered by Medicare will rise from 8.2 million...
(Date:11/26/2009)...otional rollercoaster, study finds , , T...ear factor meets the jubilant sports fan. , A n...ose who root for the winning team -- enjoy the gre...ch and victory was in doubt, producing feelings of...anksgiving weekend as you,re glued to the TV set, ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
... Therapy Appears Superior to Standard Therapy for ...omized, controlled trials comparing sequential and...nted, previously untreated H. pylori infection fo...irm these findings, 10-day sequential therapy coul...
... 19 Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH)...the,Company as Group President, Global Businesses....mer Dental, Zimmer Trauma, Zimmer Orthopaedic Surg...and Chief Executive Officer., "We are delighted t...
...tion Company Provides Development Expertise for Pa...lth Platform, PORTLAND, Ore., May 19 Mount Tabor...n and development company, announced,collaboration... headquarters today; the product allows users to s...
... polyalkylimide implant injections leaves skin ope...y 19 (HealthDay News) -- Cosmetic skin fillers cal...frequent, but sometimes severe, immune-related sid...ial features such as the lips, cheeks, forehead an...
...ing ED increased risk in diabetic men , , ...wo studies of men with diabetes add to the evidenc...y warning sign for serious heart disease. , A Hong...ly to have a heart attack or other major cardiac p...
...om University Hospitals Case Medical Center (UHCMC...der-- with malignant brain tumors are not treated ...s old. Furthermore, the researchers find that if ...pril issue of the Journal of Neurosurgery. , Usin...
Other Medicine News:Health News:Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses 2Health News:Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses 3Health News:Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses 4Health News:Mount Tabor Collaborates with Google Health 2Health News:Cosmetic Skin Fillers May Cause Delayed Side Effects 2Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 2Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 3Health News:Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment 2
Fineline EZ
Tendril DX Model 1388 K
Pediatric 6491
Flextend Model 4086
Medicine Products: